Distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies
Model-dependent changes in liver fat content, body composition, and metabolic markers are a key focus of ongoing research
Past research has shown a general alignment between GLP-1 usage and declining obesity rates across age groups, with the exception of those aged 65 and older, for whom the reported effectiveness of GLP-1 drugs is lower
January 2025: A subsection is added to the Ozempic label warning that severe gastrointestinal reactions have been reported more frequently among patients using the drug
The 2.5-milligram and 5-milligram single-dose vials of Zepbound are available for $399 a month and $549 a month, respectively, via cash, making them more accessible to people without insurance coverage for the drugs